SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalMunch-a-Biotech Today


Previous 10 Next 10 
To: nigel bates who wrote (3103)1/8/2018 11:03:30 AM
From: Biotech Jim
   of 3158
 
How can one not like ABLX has a track star as a CEO?

Oops, that was a different person with the same name.

I always liked this Ghent company.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Biotech Jim who wrote (3104)1/8/2018 2:18:15 PM
From: nigel bates
   of 3158
 
I've always been impressed just how little unusual price movement there is ahead of announcements.
Straight shooters, it seems.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: DewDiligence_on_SI1/8/2018 4:22:35 PM
   of 3158
 
Table of Biotech Buyouts of Partners (updated for Takeda-TIG): investorshub.advfn.com

Share RecommendKeepReplyMark as Last Read


To: nigel bates who wrote (3105)1/9/2018 11:17:00 AM
From: Robohogs
   of 3158
 
I remember some down days into pops. Straight as it comes.

Jon

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Robohogs who wrote (3107)1/16/2018 3:55:42 AM
From: nigel bates
   of 3158
 
Someone expects more value:

GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. on 15 January 2018.

Van Herk Investments B.V. notified Ablynx that it has crossed the 10% threshold on 12 January 2018 and now holds 7,629,229 voting securites of Ablynx, representing 10.21% of the current 74,720,644 outstanding voting rights of Ablynx (versus 9.99% notified previously on 11 October 2017).....

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: nigel bates who wrote (3108)1/16/2018 12:59:55 PM
From: olivier benrubi
   of 3158
 
Not the only one





January 16, 2018 01:01 ET | Source: Ablynx NV
multilang-release

REGULATED INFORMATION

GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Marshall Wace LLP on 12 January 2018.

Marshall Wace LLP notified Ablynx that as a result of an acquisition of voting securities, it has crossed the 3% threshold on 8 January 2018 and now holds 2,251,187 voting securities of Ablynx, representing 3.01% of the current 74,720,644 outstanding voting rights of Ablynx.

The notification contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: Marshall Wace LLP
  • Transaction date: 8 January 2018
  • Threshold that is crossed: 3%
  • Denominator: 74,720,644
  • Details of the notification: Marshall Wace LLP holds 2,251,187 Ablynx shares with voting rights

  • Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: olivier benrubi who wrote (3109)1/17/2018 4:14:38 AM
    From: nigel bates
       of 3158
     
    Interesting interview (pre-bid) with Ed Moses:
    kanaalz.knack.be

    His comments around 15:30 about how they are viewed by partners worth noting ?
    (Also, "if you ever walk around a big pharma, it feels like a mausoleum...")

    Share RecommendKeepReplyMark as Last Read


    From: nigel bates1/22/2018 5:19:10 AM
       of 3158
     
    Sanofi to Acquire Bioverativ for $11.6 Billion

    Expands Sanofi's presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion
    in other rare blood disorders Drives meaningful shareholder value with ROIC expected to exceed cost of capital within three years Enhances Sanofi's sustainable revenue and earnings growth Provides immediate Business EPS accretion[1] Paris (France) and Waltham, Mass. - January 22, 2018 - Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion (on a fully diluted basis). The transaction was unanimously approved by both the Sanofi and Bioverativ Boards of Directors.

    "With Bioverativ, a leader in the growing hemophilia market, Sanofi enhances its presence in specialty care and leadership in rare diseases, in line with its 2020 Roadmap, and creates a platform for growth in other rare blood disorders. Together, we have a great opportunity to bring innovative medicines to patients worldwide, building on Bioverativ's success in driving new standards of care with its extended half-life factor replacement therapies," commented Olivier Brandicourt, Sanofi's Chief Executive Officer. "Combined, we will continue to leverage our scientific know-how, disciplined focus and development expertise that best position us to drive value for our shareholders and create breakthrough treatments for patients."

    Bioverativ Chief Executive Officer, John Cox, noted, "Bioverativ was created to bring meaningful progress to people living with hemophilia and other rare blood disorders, and I am extremely proud of the accomplishments we've made toward that mission over the past year. We have expanded upon the success of Eloctate and Alprolix, which are making a difference in the lives of people with hemophilia every day, and built a pipeline of novel programs for people with rare blood disorders. Sanofi brings proven capabilities and a global infrastructure, which we believe will help to more rapidly expand access to our medicines globally and further our mission of transforming the lives of people with rare blood disorders. Our Chairman, Brian Posner, our entire Board and I strongly believed our spin-off would create meaningful value for shareholders, and this transaction delivers tremendous value for the shareholders who have invested in and supported our mission."

    Creating a Leading Hemophilia Portfolio

    With approximately $10 billion in annual sales and 181,000[2] people affected worldwide, hemophilia represents the largest market for rare diseases and is expected to grow above 7%[3] per year through 2022. Treatment options for patients are shaped by shifting standards of care worldwide and include prophylaxis and extended half-life products, and the development and adoption of innovative therapies.

    Bioverativ's extended half-life therapies, Eloctate® [Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein] and Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] for the treatment of hemophilia A and B, respectively, represented the first major advancements in the hemophilia market in nearly two decades when launched. In 2016, Bioverativ generated $847 million in sales and $41 million in royalties.

    Bioverativ currently markets the two products in the United States, Japan, Canada and Australia, and plans to expand into additional geographies. The therapies are also commercialized in the European Union and other countries under a collaboration agreement.

    Sanofi believes factor replacement therapy will remain the standard of care in hemophilia for many years due to excellent safety and its increasingly superior long-acting profile. Sanofi will be able to leverage Bioverativ's clinical expertise and existing commercial platform to advance fitusiran, an investigational RNA interference (RNAi) therapeutic for hemophilia A and B, with or without inhibitors. Sanofi recently announced a restructuring of its rare disease alliance with Alnylam Pharmaceuticals, with Sanofi obtaining global development and commercialization rights to fitusiran.

    Strengthening Sanofi's Specialty Care Portfolio

    One of the priorities of Sanofi's 2020 roadmap is to "Reshape the Portfolio" and focus on areas where the company currently has, or can effectively build, a leadership position. The addition of Bioverativ supports this priority by adding to our portfolio a differentiated offering of innovative therapies and providing a platform for growth in rare blood disorders, which will expand our presence in specialty care, further strengthen our leadership position in rare diseases and meet the needs of the patient community.

    Beyond its two marketed products, Bioverativ's pipeline includes a program in Phase 3 testing for cold agglutinin disease, and early stage research programs and collaborations in hemophilia, and other rare blood disorders, including sickle cell disease and beta thalassemia. Sanofi's R&D organization will support Bioverativ in bringing these important therapies to patients faster. Furthermore, Sanofi's global presence, proven expertise and success in launching specialty medicines, and established footprint in key emerging markets will help Bioverativ fully capitalize on growth opportunities for Bioverativ's current and future products.

    Delivering Shareholder Value

    The addition of Bioverativ is expected to drive meaningful value for Sanofi's shareholders, with strong cash flows from Bioverativ's growing products expected to increase Sanofi's financial and operational scale. The acquisition is expected to be immediately accretive to Sanofi's Business EPS in FY2018 and up to 5% accretive in FY2019. Sanofi is also projected to achieve ROIC in excess of cost of capital within three years. Sanofi expects to preserve its strong credit rating.

    Transaction Terms

    Under the terms of the merger agreement, Sanofi will commence a tender offer to acquire all of the outstanding shares of Bioverativ common stock at a price of $105 per share in cash. The $105 per share acquisition price represents a 64 percent premium to Bioverativ's closing price on January 19, 2018.

    The consummation of the tender offer is subject to various conditions, including the tender of at least a majority of the outstanding Bioverativ shares, redelivery of a tax opinion delivered at signing, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act and receipt of certain other regulatory approvals, and other customary conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of Sanofi will merge with Bioverativ and the outstanding Bioverativ shares not tendered in the tender offer will be converted into the right to receive the same $105 per share in cash paid in the tender offer. The tender offer is expected to commence in February 2018.

    Sanofi plans to finance the transaction with a combination of cash on hand and through new debt to be raised. The tender offer is not subject to any financing condition. Subject to the satisfaction or waiver of customary closing conditions, the transaction is expected to close within three months.

    Lazard is acting as exclusive financial advisor to Sanofi. Guggenheim Securities and J.P. Morgan Securities LLC are acting as financial advisors to Bioverativ. Weil, Gotshal & Manges LLP is serving as legal counsel to Sanofi. Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as legal counsel to Bioverativ.

    Conference Call

    Sanofi will host a webcast live on Sanofi's website at 2:00 pm CET/8:00 am EST on Monday, January 22, 2018. The webcast details and full presentation will be made available on Sanofi's Investor Relations webpage.

    Share RecommendKeepReplyMark as Last Read


    From: nigel bates1/29/2018 4:44:25 AM
       of 3158
     
    Sanofi rides in as white knight - though I still think it's being sold cheap.

  • PARIS, France and GHENT, Belgium, 29 January 2018 – Sanofi [Euronext: SAN; NYSE: SNY] and Ablynx [Euronext Brussels and Nasdaq: ABLX], a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion. The transaction was unanimously approved by both the Sanofi and Ablynx Boards of Directors.




  • Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: nigel bates who wrote (3112)1/29/2018 11:07:36 AM
    From: Miljenko Zuanic
       of 3158
     
    Why was Ablynx BofD inclined to sell comp so early? Aware of risk involved, or....something more obvious????

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)
    Previous 10 Next 10